الصفحة الرئيسية>>XZ739

XZ739

رقم الكتالوجGC61384

XZ739 ، جهاز طرد PROTAC BCL-XL يعتمد على Cereblon (أحد أفراد عائلة Bcl-2) بقيمة DC50 تبلغ 2.5 نانومتر في خلايا MOLT-4 بعد 16 ساعة من العلاجيحث XZ739 أيضًا على موت الخلايا من خلال موت الخلايا المبرمج بوساطة كاسباس

Products are for research use only. Not for human use. We do not sell to patients.

XZ739 التركيب الكيميائي

Cas No.: 2365172-19-4

الحجم السعر المخزون الكميّة
5mg
1437٫00
متوفر
10mg
2364٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

XZ739, a CRBN-dependent PROTAC BCL-XL degrader with a DC50 value of 2.5 nM in MOLT-4 cells after 16 h treatment. XZ739 also induces cell death through caspase-mediated apoptosis[1].

XZ739 (0.001-10 μM; 48 hours) potently reduces the viability of T-ALL MOLT-4, B-ALL RS4; 11, SCLC NCI-H146 cells, and platelets after 48 h treatment with IC50s of 10.1, 41.8, 25.3, and 1217 nM, respectively. XZ739 has >100-fold selectivity for MOLT-4 cells over human platelets[1].XZ739 (1.2-300 nM; 16 hours) induces BCL-XL degradation in MOLT-4 cells[1]. The BCL-XL degradation induced by XZ739 in MOLT-4 is rapid, starting within 2 h; and 8 h after XZ739 treatment, more than 96% of the BCL-XL is degraded with 100 nM of XZ739[1]. Cell Viability Assay[1] Cell Line: Human platelets and MOLT-4 cells

[1]. Xuan Zhang,et al. Discovery of PROTAC BCL-X L Degraders as Potent Anticancer Agents With Low On-Target Platelet Toxicity. Eur J Med Chem. 2020 Apr 15;192:112186.

مراجعات

Review for XZ739

Average Rating: 5 ★★★★★ (Based on Reviews and 37 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for XZ739

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.